Roche Launches Elecsys PRO-C3 Test to Advance Precision in Liver Fibrosis Diagnostics
SHERIDAN, WYOMING – May 27, 2025 – Roche has introduced its Elecsys® PRO-C3 diagnostic test, marking a major step forward in the assessment of liver fibrosis severity, particularly in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). With the ability to deliver results in just 18 minutes, the new test is poised to streamline diagnostics and enable earlier, more accurate clinical decision-making.
Strategic Response to a Global Health Burden
MASLD, affecting approximately 30% of the global population, is increasingly prevalent due to rising rates of diabetes, obesity, and other cardiometabolic risk factors. While it contributes to around one in every 25 deaths globally, liver fibrosis associated with MASLD often progresses unnoticed until late stages, escalating risks of cirrhosis, liver failure, and cancer.